Sarepta Therapeutics Option Alert: Jan 16 $135 Puts at the Bid: 260 vs 823 OI; Earnings 4/30 After Close [est] 

Sarepta Therapeutics Option Alert: Jan 16 $135 Puts at the Bid: 260 @ $62.0 vs 823 OI; Earnings 4/30 After Close [est] Ref=$73.52

Sarepta Therapeutics Bolsa (NASDAQ: SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Bolsa

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5
–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3
–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Data expected for SRP-9003 for LGMD2E/R4 by mid-2025
Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4.
<ul>
<li>SRP-9005 for LGMD type 2C/R5: Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (OTP), Sarepta is cleared to proceed with dosing in Study SRP-9005-101 (COMPASS) in the U.S. COMPASS is a first-in-human clinical study of SRP-9005, an investigational gene therapy for LGMD type 2C/R5, or gamma-sarcoglycanopathy.</li>
<li>SRP-9004 for LGMD type 2D/R3: Enrollment and dosing is complete in Study SRP-9004-102 (DISCOVERY).DISCOVERY is a phase 1, proof-of-concept study evaluating safety and expression of the alpha-sarcoglycan protein after treatment with SRP-9004, an investigational gene therapy for the treatment of LGMD type 2D/R3, or alpha-sarcoglycanopathy.</li>
<li>SRP-9003 for LGMD type 2E/R4: Enrollment and dosing is complete in Study SRP-9003-301 (EMERGENE). EMERGENE is a phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of LGMD type 2E/R4, or beta-sarcoglycanopathy. EMERGENE is a global study and the primary endpoint is the biomarker expression of beta-sarcoglycan protein. A pre-Biologics License Application (BLA) meeting has occurred and the OTP has confirmed eligibility for the accelerated approval pathway for the program. Sarepta remains on track to submit a BLA to the U.S. FDA in the second half of 2025.</li>
</ul>

News

SRPT

Sarepta Issues Update From Clinical Programs Focused On LGMD Subtypes 2C/R5, 2D/R3, And 2E/R4; FDA Confirmed That Screening, Dosing May Proceed In Study SRP-9005-101 For Lgmd2C/R5

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $196 to $182.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $182

Wells Fargo analyst Yanan Zhu initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight rating and announces Price Target of $115.

Initiation

Wells Fargo Initiates Coverage On Sarepta Therapeutics with Overweight Rating, Announces Price Target of $115

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $75 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target

In March,&nbsp;Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
The company reported a patient death following treatment with Elevidys, having suffered <a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.
On Wednesday, Sarepta and Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) temporarily <a target="_blank" href="https://www.duchenneuk.org/roche-temporarily-halts-clinic-studies/" rel="noreferrer noopener">halted</a> several clinical studies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43232532/sarepta-therapeutics-duchenne-gene-therapy-shows-sustained-benefits-and-disease-stabilization-at-two-years" rel="noreferrer noopener">Sarepta Therapeutics&#8217; Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years</a>
Roche, the company to which the treatment is licensed outside the US, has said that this was at the European Medicines Agency&#8217;s (EMA) request.
The companies have a therapeutic clinical hold on Study 104, Study 302, and Study 303 in the EU until the analysis of the cause of death is complete.
Roche is also pausing the enrollment and dosing of participants in the U.K. for its ENVOL study.
Patient safety monitoring for already enrolled participants and ongoing collection of data will continue.
In June 2024, the EMA validated and <a target="_blank" href="https://www.roche.com/investors/updates/inv-update-2024-06-24" rel="noreferrer noopener">initiated</a> a review of the marketing authorization application for Elevidys, a gene therapy for ambulatory patients aged 3-7 years old with Duchenne muscular dystrophy.
HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range.
Analyst Mitchell S. Kapoor still anticipates Elevidys revenue will fall short in the second half of 2025—especially after the recent patient death due to acute liver injury.
Kapoor sees a risk that Elevidys sales may decline faster than expected, possibly as early as Q2 2025, due to growing hesitation from doctors and patients regarding its safety. The treatment&#8217;s limited effectiveness heightens this concern.
The analyst maintains the price <a target="_blank" href="https://www.benzinga.com/quote/SRPT/analyst-ratings" rel="noreferrer noopener">forecast of $75 per share</a>.
Needham maintained Sarepta Therapeutics with a Buy, lowering the price forecast from $202 to $183.
Price Action: SRPT stock is down 6.68% at $58.30 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44631273/novartis-secures-third-fda-approval-for-its-kidney-disease-portfolio-in-one-year" target="_blank" rel="noreferrer noopener">Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year</a></li>
</ul>
Image via Sarepta Therapeutics

Analyst Color

Biotech

Large Cap

Movers

Trading Ideas

General

RHHBY

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Investors with significant funds have taken a bearish position in Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in SRPT usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 9 options transactions for Sarepta Therapeutics. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 11% being bullish and 77% bearish. Of all the options we discovered, 8 are puts, valued at $395,971, and there was a single call, worth $61,500.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $60.0 for Sarepta Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Sarepta Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Sarepta Therapeutics's substantial trades, within a strike price spectrum from $60.0 to $60.0 over the preceding 30 days.
<h3>Sarepta Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743693968_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$2.5</td>
<td>$1.85</td>
<td>$1.9</td>
<td>$60.00</td>
<td>$95.0K</td>
<td>5.7K</td>
<td>5.2K</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.2</td>
<td>$60.00</td>
<td>$81.8K</td>
<td>5.7K</td>
<td>3.3K</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$12.7</td>
<td>$12.0</td>
<td>$12.3</td>
<td>$60.00</td>
<td>$61.5K</td>
<td>273</td>
<td>1</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$2.0</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$60.00</td>
<td>$42.8K</td>
<td>5.7K</td>
<td>4.5K</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$1.7</td>
<td>$1.45</td>
<td>$1.7</td>
<td>$60.00</td>
<td>$42.1K</td>
<td>5.7K</td>
<td>5.4K</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
After a thorough review of the options trading surrounding Sarepta Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Sarepta Therapeutics</h3>
<ul>
<li>With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for Sarepta Therapeutics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $106.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $87. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Sarepta Therapeutics, which currently sits at a price target of $80. 
&#x2A; In a positive move, an analyst from HC Wainwright &amp; Co. has upgraded their rating to Neutral and adjusted the price target to $75. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Sarepta Therapeutics with a target price of $183. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Perform with a price target of $105. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Smart Money Is Betting Big In SRPT Options

WIIM

Sarepta Therapeutics shares are trading lower after Needham cut its price target on the stock from $202 to $183.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $265 to $250. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Apple shares closed at $223.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities raised the price target for The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from $180 to $185. Truist Securities analyst Bill Chappell maintained a Buy rating. Procter &amp; Gamble shares closed at $169.50 on Wednesday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) price target from $212.5 to $186.5. JP Morgan analyst Andrew Dietrich maintained a Neutral rating. M&amp;T Bank shares closed at $179.71 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">view this stock</a>.</li>
<li>Morgan Stanley cut the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $530 to $300. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating. RH shares closed at $249.35 on Wednesday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods cut the price target for nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from $40 to $28. Keefe, Bruyette &amp; Woods analyst Ryan Tomasello maintained an Outperform rating. nCino shares closed at $22.59 on Wednesday. <a href="https://www.benzinga.com/quote/NCNO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group cut Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) price target from $40 to $27. Evercore ISI Group analyst Amit Daryanani downgraded the stock from Outperform to In-Line. Sensata Technologies shares settled at $24.61 on Wednesday. <a href="https://www.benzinga.com/quote/ST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) price target from $54 to $44. Jefferies analyst Sean Milligan maintained an Underperform rating. Enphase Energy shares closed at $62.52 on Wednesday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised Sportradar Group AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) price target from $30 to $32. Canaccord Genuity analyst Michael Graham maintained a Buy rating. Sportradar shares closed at $22.20 on Wednesday.  <a href="https://www.benzinga.com/quote/SRAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird slashed the price target for Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) from $46 to $43. Baird analyst Andrew Wittmann maintained a Neutral rating. Fluor shares settled at $37.22 on Wednesday. <a href="https://www.benzinga.com/quote/FLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) price target from $202 to $183. Needham analyst Gil Blum maintained a Buy rating. Sarepta Therapeutics shares closed at $62.47 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-1024x590.png" alt="" class="wp-image-855474" style="width:516px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AAPL

ENPH

NCNO

SRAD

Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">5</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current average has decreased by 7.25% from the previous average price target of $137.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1743681614_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Sarepta Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$87.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$99.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$161.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Sarepta Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
<h3>Sarepta Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Sarepta Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 65.94%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 24.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 11.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sarepta Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.88, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and lowers the price target from $202 to $183.

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $183

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintained the price target of $75. Sarepta Therapeutics shares closed at $61.91 on Tuesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jimmy Bhullar upgraded Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) from Neutral to Overweight and raised the price target from $232 to $237. Reinsurance Group shares closed at $198.27 on Tuesday. <a href="https://www.benzinga.com/quote/RGA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Christopher Allen upgraded the rating for The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) from Neutral to Buy and lifted the price target from $85 to $102. Charles Schwab shares closed at $77.67 on Tuesday. <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Will Nance upgraded Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) from Neutral to Buy and raised the price target from $246 to $260. Fiserv shares closed at $222.01 on Tuesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Bill Chappell upgraded The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) from Hold to Buy and maintained the price target of $70. Scotts Miracle Gro shares closed at $54.77 on Tuesday.  <a href="https://www.benzinga.com/quote/SMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-1024x595.png" alt="" class="wp-image-853451" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24.png 1086w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo via Shutterstock

Upgrades

SCHW

This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

HC Wainwright &amp; Co. analyst Mitchell Kapoor upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintains the price target from $75 to $75.

HC Wainwright & Co. Upgrades Sarepta Therapeutics to Neutral, Maintains Price Target to $75

Sarepta Therapeutics shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform and lowered the price target from $161 to $87.

RBC Capital analyst Brian Abrahams downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Sector Perform and lowers the price target from $161 to $87.

Downgrades

RBC Capital Downgrades Sarepta Therapeutics to Sector Perform, Lowers Price Target to $87

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SRPT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Sarepta Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 18% bearish. Among these notable options, 4 are puts, totaling $282,850, and 7 are calls, amounting to $233,830.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $140.0 for Sarepta Therapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Sarepta Therapeutics stands at 172.62, with a total volume reaching 607.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Sarepta Therapeutics, situated within the strike price corridor from $70.0 to $140.0, throughout the last 30 days.
<h3>Sarepta Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742584593_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.9</td>
<td>$30.3</td>
<td>$30.3</td>
<td>$100.00</td>
<td>$99.9K</td>
<td align="right">637</td>
<td align="right">63</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.4</td>
<td>$29.8</td>
<td>$30.4</td>
<td>$100.00</td>
<td>$72.9K</td>
<td align="right">637</td>
<td align="right">24</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$68.2</td>
<td>$64.2</td>
<td>$66.16</td>
<td>$140.00</td>
<td>$66.1K</td>
<td align="right">10</td>
<td align="right">10</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$24.6</td>
<td>$24.1</td>
<td>$24.3</td>
<td>$95.00</td>
<td>$43.7K</td>
<td align="right">142</td>
<td align="right">19</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$8.9</td>
<td>$8.4</td>
<td>$8.65</td>
<td>$80.00</td>
<td>$43.2K</td>
<td align="right">548</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Having examined the options trading patterns of Sarepta Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Sarepta Therapeutics</h3>
<ul>
<li>With a volume of 1,192,820, the price of SRPT is down -0.2% at $73.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 40 days.</li>
</ul>
<h3>What The Experts Say On Sarepta Therapeutics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $141.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Perform, setting a price target of $105. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $163. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $163. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $202. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Sell, setting a price target of $75. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Sarepta Therapeutics

Sarepta Therapeutics shares are trading lower after Scotiabank cut its price target on the stock from $105 to $80.

Scotiabank analyst Louise Chen maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sector Perform and lowers the price target from $105 to $80.

Scotiabank Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $80

Sarepta Therapeutics shares are trading higher. The stock fell on Tuesday after the company reported a patient death following treatment with Elevidys.

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and maintains $163 price target.

Cantor Fitzgerald Reiterates Overweight on Sarepta Therapeutics, Maintains $163 Price Target

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Provides Update on ELEVIDYS

NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Comments

Sarepta Therapeutics

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL